Document:

EX-4.10

 Exhibit 4.10 

REGISTRATION RIGHTS AGREEMENT 

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of
            , 2014, among Q THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each signatory hereto (each, an “Investor” and
collectively, the “Investors”). 
 R E C I T A L S 

WHEREAS, the Company and the Investors are parties to Subscription Agreements (the “Subscription Agreements”) entered into in
connection with a private placement offering (the “Offering”) of certain units (the “Units”) for $1.00 per Unit, each Unit consisting of (i) one share of the Company’s common stock, par value $0.0001 per
share (“Common Stock”), and (ii) one warrant to purchase one (1.00) share of Common Stock from the date of issuance until the fourth anniversary date of the date of issuance for $1.00 per share, subject to adjustment (the
“Warrants”), solely to “accredited investors” under Section 4(2) and Rule 506 of Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and non-U.S. persons
pursuant to Regulation S promulgated under the Securities Act; 
 WHEREAS, the Investors’ obligations under the Subscription Agreements
are conditioned upon certain registration rights for the shares of Common Stock underlying the Units (the “Shares”) and the shares of Common Stock issuable upon the exercise of the Warrants (the “Warrant Shares,”
and with the Shares, the “Registrable Securities”) under the Securities Act; and 
 WHEREAS, the Investors and the Company
desire to provide for the rights of registration of the Registrable Securities under the Securities Act as are provided herein upon the execution and delivery of this Agreement by such Investors and the Company. 

NOW, THEREFORE, in consideration of the promises, covenants and conditions set forth herein, the parties hereto hereby agree as follows: 

1. Registration Rights. 
 1.1
Definitions. As used in this Agreement, the following terms shall have the meanings set forth below: 
 (a) “Final Closing
Date” means the date of the last closing of the Offering. 
 (b) “Commission” means the United States Securities
and Exchange Commission. 
 (c) “Common Stock” means the Company’s common stock, par value $0.0001 per share. 

(d) “Effectiveness Date” means the date that is one hundred eighty (180) days after the Final Closing Date for the
Shares. 

 (e) “Effectiveness Period” shall mean a period commencing on the date the
Commission declares the Registration Statement to be effective under the Securities Act until the earlier of (i) the one year anniversary of such date or (ii) the date on which all of the Registrable Securities included in the Registration
Statement are sold or may be sold pursuant to Rule 144. 
 (f) “Exchange Act” means the Securities Exchange Act of 1934, as
amended. 
 (g) “Filing Date” means the date that is forty five (45) days after the Final Closing Date for the Shares.

 (h) “Investor” means any person owning Registrable Securities who becomes party to this Agreement by executing a
counterpart signature page hereto, or other agreement in writing to be bound by the terms hereof, which is accepted by the Company. 
 (i)
The terms “register,” “registered” and “registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Securities Act, and
the declaration or ordering of effectiveness of such registration statement or document. 
 (j) “Registrable Securities”
mean any of the Shares and Warrant Shares or any securities issued or issuable as (or any securities issued or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other distribution with
respect to, or in exchange for, or in replacement of, the Shares or Warrant Shares; provided, however, that Registrable Securities shall not include any securities of the Company that have previously been registered and remain subject
to a currently effective registration statement or which have been sold to the public either pursuant to a registration statement or Rule 144, or which have been sold in a private transaction in which the transferor’s rights under this
Section 1 are not assigned, or which may be sold immediately without registration under the Securities Act and without volume restrictions pursuant to Rule 144. 

(k) “Rule 144” means Rule 144 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time
to time, or any similar successor rule that may be promulgated by the Commission. 
 (l) “Rule 415” means Rule 415 as
promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. 

(m) “Shares” mean the shares of Common Stock of the Company underlying the Units. 

(n) “Warrants” mean the Warrants to purchase Common Stock issued pursuant to the Subscription Agreement in connection with the
Offering. 
 (o) “Warrant Shares” mean the Shares issued or issuable upon the exercise of the Warrants. 

  
 2 

 1.2 Company Registration. 

(a) Shares. As soon as possible following the Final Closing Date, but in any event not later than 45 days following the Final Closing
Date, the Company shall prepare a registration statement covering the Shares for an offering to be made on a continuous basis pursuant to Rule 415. The registration statement shall be on Form S-1 (except if the Company is not then eligible to
register for resale the Registrable Securities on Form S-1, in which case such registration shall be on another appropriate form in accordance herewith) (the “Registration Statement”) and shall contain (unless otherwise directed by
Investors holding an aggregate of at least 75% of the Shares, on a fully diluted basis) substantially the “Plan of Distribution” attached hereto as Annex A. The Company shall use its commercially reasonable efforts to file
the Registration Statement no later than the Filing Date for the Shares and shall use its commercially reasonable efforts to cause the Registration Statement to be declared effective under the Securities Act as soon as possible and, in any event, by
the Effectiveness Date. The Company shall use its commercially reasonable efforts to keep the Registration Statement continuously effective under the Securities Act throughout the Effectiveness Period. 

(b) [Intentionally Left Blank.]  

(c) If during the Effectiveness Period of a Registration Statement, the number of Registrable Securities at any time exceeds 100% of the Shares
or Warrant Shares, as the case may be, then registered in a Registration Statement, the Company shall file as soon as reasonably practicable an additional Registration Statement or Registration Statements covering the resale of not less than the
number of such Registrable Securities. 
 (d) The Company shall bear and pay all expenses incurred in connection with any registration,
filing or qualification of Registrable Securities with respect to the registrations pursuant to this Section 1.2 for each Investor, including (without limitation) all registration, filing and qualification fees, printer’s fees, accounting
fees and fees and disbursements of counsel for the Company, but excluding any brokerage or underwriting fees, discounts and commissions relating to Registrable Securities and fees and disbursements of counsel for the Investors. 

1.3 Obligations of the Company. Whenever required under this Section 1 to effect the registration of any Registrable Securities,
the Company shall, as expeditiously as reasonably possible: 
 (a) Prepare and file with the Commission a Registration Statement with respect
to such Registrable Securities and use commercially reasonable efforts to cause such Registration Statement to become effective and to keep such Registration Statement effective during the Effectiveness Period; 

(b) Prepare and file with the Commission such amendments and supplements to such Registration Statement and the prospectus used in connection
with such Registration Statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such Registration Statement; 

  
 3 

 (c) Furnish to the Investors such numbers of copies of a prospectus, including a preliminary
prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them (provided that the Company would not be
required to print such prospectuses if readily available to Investors from any electronic service, such as on the EDGAR filing database maintained at www.sec.gov); 

(d) Use commercially reasonable efforts to register and qualify the securities covered by such Registration Statement under such other
securities’ or blue sky laws of such jurisdictions as shall be reasonably requested by the Investors; provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a
general consent to service of process in any such states or jurisdictions; 
 (e) In the event of any underwritten public offering, enter
into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter(s) of such offering (each Investor participating in such underwriting shall also enter into and perform its obligations
under such an agreement); 
 (f) Promptly notify each Investor holding Registrable Securities covered by such Registration Statement at any
time when a prospectus relating thereto is required to be delivered under the Securities Act, within one business day, (i) of the effectiveness of such Registration Statement, or (ii) of the happening of any event as a result of which the
prospectus included in such Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the
light of the circumstances then existing; 
 (g) Cause all such Registrable Securities registered pursuant hereto to be listed on each
securities exchange or nationally recognized quotation system on which similar securities issued by the Company are then listed; and 
 (h)
Provide a transfer agent and registrar for all Registrable Securities registered pursuant hereunder and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration. 

1.4 Furnish Information. It shall be a condition precedent to the Company’s obligations to take any action pursuant to this
Section 1 with respect to the Registrable Securities of any selling Investor that such Investor shall furnish to the Company such information regarding such Investor, the Registrable Securities held by such Investor, and the intended method of
disposition of such securities in the form attached to this Agreement as Annex B, or as otherwise reasonably required by the Company or the managing underwriters, if any, to effect the registration of such Investor’s Registrable
Securities. 
 1.5 Delay of Registration. No Investor shall have any right to obtain or seek an injunction restraining or otherwise
delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1. 

  
 4 

 1.6 Indemnification. 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each Investor, any underwriter (as defined in the Securities
Act) for such Investor and each person, if any, who controls such Investor or underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages or liabilities (joint or several) to which any of the
foregoing persons may become subject under the Securities Act, the Exchange Act or other federal or state securities law, insofar as in each case to the extent (and only to the extent) such losses, claims, damages or liabilities (or actions in
respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively, a “Violation”): (i) any untrue statement or alleged untrue statement of a material fact contained in a
Registration Statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto (collectively, the “Filings”), (ii) the omission or alleged omission to state in the
Filings a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or
any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law; and the Company will pay any legal or other expenses reasonably incurred by any person to be indemnified pursuant to this Section 1.6(a)
in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity agreement contained in this Section 1.6(a) shall not apply to amounts paid in settlement of any
such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage,
liability or action to the extent that it arises out of or is based upon a Violation that occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by any such Investor,
underwriter or controlling person. 
 (b) To the extent permitted by law, each Investor will indemnify and hold harmless the Company, each of
its directors, each of its officers who has signed the Registration Statement, each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act, any underwriter, any other Investor selling securities in such
Registration Statement and any controlling person of any such underwriter or other Investor, against any losses, claims, damages or liabilities (joint or several) to which any of the foregoing persons may become subject under the Securities Act, the
Exchange Act or other federal or state securities law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such
Violation occurs in reliance upon and in conformity with written information furnished by such Investor expressly for use in connection with such registration; and each such Investor will pay any legal or other expenses reasonably incurred by any
person to be indemnified pursuant to this Section 1.6(b) in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity agreement contained in this
Section 1.6(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Investor (which consent shall not be unreasonably withheld);
provided, however, in no event shall any indemnity under this subsection 1.6(b) exceed the net proceeds received by such Investor upon the sale of the Registrable Securities giving rise to such indemnification obligation. 

  
 5 

 (c) Promptly after receipt by an indemnified party under this Section 1.6 of notice of the
commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.6, deliver to the indemnifying party a written notice
of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with
counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one
separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests
between such indemnified party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if materially
prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section 1.6, but the omission so to deliver written notice to the indemnifying party will not relieve
it of any liability that it may have to any indemnified party otherwise than under this Section 1.6. 
 (d) If the indemnification
provided for in Sections 1.6(a) and (b) is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, claim, damage or expense referred to herein, then the indemnifying party, in lieu of
indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the
indemnifying party on the one hand and of the indemnified party on the other in connection with the statements or omissions or alleged statements or omissions that resulted in such loss, liability, claim or expense as well as any other relevant
equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact relates to information
supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. In no event shall any Investor be required to
contribute an amount in excess of the net proceeds received by such Investor upon the sale of the Registrable Securities giving rise to such indemnification obligation. 

(e) The obligations of the Company and Investors under this Section 1.6 shall survive the completion of any offering of Registrable
Securities in a registration statement under this Section 1, and otherwise. 
 1.7 Reports Under Securities Exchange Act. With a
view to making available the benefits of certain rules and regulations of the Commission, including Rule 144, that may at any time permit an Investor to sell securities of the Company to the public without registration or pursuant to a registration
on Form S-1, the Company agrees to: 

  
 6 

 (a) make and keep public information available, as those terms are understood and defined in Rule
144, at all times after the date of the Subscription Agreement; 
 (b) take such action, including the voluntary registration of its Common
Stock under Section 12 of the Exchange Act, as is necessary to enable the Investors to utilize Form S-1 for the sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the fiscal year in which the
Registration Statement is declared effective; 
 (c) file with the Commission in a timely manner all reports and other documents required of
the Company under the Securities Act and the Exchange Act; and 
 (d) furnish to any Investor, so long as the Investor owns any Registrable
Securities, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144, the Securities Act and the Exchange Act, or that it qualifies as a registrant whose securities may be
resold pursuant to Form S-1 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may
be reasonably requested in availing any Investor of any rule or regulation of the Commission that permits the selling of any such securities without registration or pursuant to such form. 

1.8 Transfer or Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to this
Section 1 may be transferred or assigned, but only with all related obligations, by an Investor to a transferee or assignee who (a) acquires at least 50,000 Registrable Securities (subject to appropriate adjustment for stock splits, stock
dividends and combinations) from such transferring Investor, unless waived in writing by the Company, or (b) holds Registrable Securities immediately prior to such transfer or assignment; provided, that in the case of (a), (i) prior
to such transfer or assignment, the Company is furnished with written notice stating the name and address of such transferee or assignee and identifying the securities with respect to which such registration rights are being transferred or assigned,
(ii) such transferee or assignee agrees in writing to be bound by and subject to the terms and conditions of this Agreement and (iii) such transfer or assignment shall be effective only if immediately following such transfer or assignment
the further disposition of such securities by the transferee or assignee is restricted under the Securities Act. 
 1.9. Rule 415.
Notwithstanding anything contained herein to the contrary, the Investor expressly acknowledges that it is possible that the Commission may not permit the Company to register all of the Shares or Warrant Shares, as the case may be, for resale in one
Registration Statement. In the event the Company is prohibited from registering all of the Shares or Warrant Shares, as the case may be, in one Registration Statement by the Commission under Rule 415 or any other rule or regulation, the Company
shall register the maximum number of Shares or Warrant Shares, as the case may be, permitted in the Registration Statement on a pro rata basis and shall use its commercially reasonable efforts to file one or more additional Registration Statements
as soon as possible thereafter until all of the Shares and Warrant Shares are registered under the Securities Act. 

  
 7 

 2. Legend. 

(a) Until registered pursuant to an effective Registration Statement, each certificate representing Registrable Securities held by the
Investors shall be endorsed with the following legend: 
 “THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO SUCH SECURITIES UNDER THE ACT
OR AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THIS CERTIFICATE THAT AN EXEMPTION FROM THE REGISTRATION REUIREMENTS OF THE ACT IS AVAILABLE WITH RESPECT TO SUCH TRANSFER. ANY SUCH TRANSFER MAY ALSO BE SUBJECT TO COMPLIANCE WITH APPLICABLE
STATE SECURITIES LAWS.” 
 (b) The legend set forth above shall be removed, and the Company shall issue a certificate without such
legend to the transferee of the Registrable Securities represented thereby, if, unless otherwise required by state securities laws, (i) such Registrable Securities have been sold under an effective Registration statement under the Securities
Act, (ii) in connection with a sale, assignment or other transfer, such holder provides the Company with an opinion of counsel, reasonably acceptable to the Company, to the effect that such sale, assignment or transfer is being made pursuant to
an exemption from the registration requirements of the Securities Act, or (iii) such holder provides the Company with reasonable assurance that the Registrable Securities are being sold, assigned or transferred pursuant to Rule 144 or Rule 144A
under the Securities Act. 
 3. Miscellaneous. 

3.1 Governing Law. Notwithstanding the place where this Registration Rights Agreement may be executed by any of the parties hereto, the
parties expressly agree that the terms and provisions hereof shall be construed in accordance with and governed by the laws of the State of Delaware. The Company and Investor hereby agree that any dispute which may arise between them arising out of
or in connection with this Agreement shall be adjudicated before a court located in Salt Lake City, Utah and they hereby submit to the exclusive jurisdiction of the federal and state courts of the State of Utah located in Salt Lake City with respect
to any action or legal proceeding commenced by any party, and irrevocably waive any objection they now or hereafter may have respecting the venue of any such action or proceeding brought in such a court or respecting the fact that such court is an
inconvenient forum, relating to or arising out of this Agreement or any acts or omissions relating to the sale of the securities hereunder, and consent to the service of process in any such action or legal proceeding by means of registered or
certified mail, return receipt requested, in care of the address set forth herein or such other address as either party shall furnish in writing to the other. 

  
 8 

 3.2 Waivers and Amendments. This Agreement may be terminated and any term of this
Agreement may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) with the written consent of the Company and Investors holding at least a majority of the Registrable Securities then
outstanding (the “Majority Investors”). Notwithstanding the foregoing, additional parties may be added as Investors under this Agreement, and the definition of Registrable Securities expanded, with the written consent of the Company
and the Majority Investors. No such amendment or waiver shall reduce the aforesaid percentage of the Registrable Securities, the holders of which are required to consent to any termination, amendment or waiver without the consent of the record
holders of all of the Registrable Securities. Any termination, amendment or waiver effected in accordance with this Section 3.2 shall be binding upon each holder of Registrable Securities then outstanding, each future holder of all such
Registrable Securities and the Company. 
 3.3 Successors and Assigns. Except as otherwise expressly provided herein, the provisions
of this Agreement shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto. 

3.4 Entire Agreement. This Agreement constitutes the full and entire understanding and agreement among the parties with regard to the
subject matter hereof, and no party shall be liable or bound to any other party in any manner by any warranties, representations or covenants except as specifically set forth herein. 

3.5 Notices. All notices and other communications required or permitted under this Agreement shall be in writing and shall be delivered
personally by hand or by overnight courier, mailed by United States first-class mail, postage prepaid, sent by facsimile or sent by electronic mail directed (a) if to an Investor, at such Investor’s address, facsimile number or electronic
mail address set forth in the Company’s records, or at such other address, facsimile number or electronic mail address as such Investor may designate by ten (10) days’ advance written notice to the other parties hereto or (b) if
to the Company, to its address, facsimile number or electronic mail address set forth on its signature page to this Agreement and directed to the attention of Steven J. Borst, Chief Financial Officer, or at such other address, facsimile number or
electronic mail address as the Company may designate by ten (10) days’ advance written notice to the other parties hereto. All such notices and other communications shall be effective or deemed given upon delivery, on the date that is
three (3) days following the date of mailing, upon confirmation of facsimile transfer or upon confirmation of electronic mail delivery. 

3.6 Interpretation. The words “include,” “includes” and “including” when used herein shall be deemed in
each case to be followed by the words “without limitation.” The titles and subtitles used in this Agreement are used for convenience only and are not considered in construing or interpreting this Agreement. 

3.7 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be
excluded from this Agreement, and the balance of the Agreement shall be interpreted as if such provision were so excluded, and shall be enforceable in accordance with its terms. 

  
 9 

 3.8 Independent Nature of Investors’ Obligations and Rights. The obligations of each
Investor hereunder are several and not joint with the obligations of any other Investor hereunder, and no Investor shall be responsible in any way for the performance of the obligations of any other Investor hereunder. Nothing contained herein or in
any other agreement or document delivered at any closing, and no action taken by any Investor pursuant hereto or thereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or
create a presumption that the Investors are in any way acting in concert with respect to such obligations or the transactions contemplated by this Agreement. Each Investor shall be entitled to protect and enforce its rights, including without
limitation the rights arising out of this Agreement, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. 

3.9 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which
together shall constitute one instrument. 
 3.10 Telecopy Execution and Delivery. A facsimile, telecopy or other reproduction of this
Agreement may be executed by one or more parties hereto, and an executed copy of this Agreement may be delivered by one or more parties hereto by facsimile or similar electronic transmission device pursuant to which the signature of or on behalf of
such party can be seen, and such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to execute an original of this Agreement as well as any
facsimile, telecopy or other reproduction hereof. 
 [SIGNATURE PAGE FOLLOWS] 

  
 10 

 IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its duly authorized
officer, as of the date, month and year first set forth above. 
  

			
	 “Company”

	
	Q THERAPEUTICS, INC.
		
	By:	 	 
	 Name:
	 	
	 Title:
	 	
	
	 Address for notice:

	 Q THERAPEUTICS, INC.

	 615 ARAPEEN DRIVE, SUITE 102

	 SALT LAKE CITY, UTAH 84108

 [COMPANY SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT] 

 IN WITNESS WHEREOF, the undersigned Investor has executed this Agreement as of the date, month
and year that such Investor became the owner of Registrable Securities. 
  

			
	 “Investor”

	 
		
	By:	 	 
	 Name
	 	
	 Title:
	 	

 
			
		
	 Address:
	 	
	 
	 
	 

 
			
	 Telephone:
	 	 
	 Facsimile:
	 	 

 
			
	 Email:
	 	 

 [INVESTOR COUNTERPART SIGNATURE PAGE TO 

REGISTRATION RIGHTS AGREEMENT] 

 Annex A 

Plan of Distribution 

Each selling stockholder of the Common Stock and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any
or all of their shares of Common Stock on the [NAME OF PRINCIPAL TRADING MARKET] or any other stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. A
selling stockholder may use any one or more of the following methods when selling shares: 
  

	 	•	 	ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; 

  

	 	•	 	block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; 

 

	 	•	 	purchases by a broker-dealer as principal and resale by the broker-dealer for its account; 

  

	 	•	 	an exchange distribution in accordance with the rules of the applicable exchange; 

  

	 	•	 	privately negotiated transactions; 

  

	 	•	 	settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part; 

  

	 	•	 	broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share; 

  

	 	•	 	through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; 

  

	 	•	 	a combination of any such methods of sale; or 

  

	 	•	 	any other method permitted pursuant to applicable law. 

 The selling stockholders may also sell
shares under Rule 144 under the Securities Act of 1933, as amended, if available, rather than under this prospectus. 
 Broker-dealers
engaged by the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares,
from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case
of a principal transaction a markup or markdown in compliance with FINRA IM-2440. 

 In connection with the sale of the common stock or interests therein, the selling stockholders
may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of
the common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other
transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares
such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). 

The selling stockholders and any broker-dealers or agents that are involved in selling the shares may be deemed to be “underwriters”
within the meaning of the Securities Act of 1933, as amended, in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be
underwriting commissions or discounts under the Securities Act of 1933, as amended. Each selling stockholder has informed us that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute
the common stock. In no event shall any broker-dealer receive fees, commissions and markups which, in the aggregate, would exceed eight percent (8%). 

We are required to pay certain fees and expenses incurred by us incident to the registration of the shares. We have agreed to indemnify the
selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act of 1933, as amended. 

Because selling stockholders may be deemed to be “underwriters” within the meaning of the Securities Act of 1933, as amended, they
will be subject to the prospectus delivery requirements of the Securities Act of 1933, as amended, including Rule 172 thereunder. In addition, any securities covered by this prospectus which qualify for sale pursuant to Rule 144 under the Securities
Act of 1933, as amended may be sold under Rule 144 rather than under this prospectus. There is no underwriter or coordinating broker acting in connection with the proposed sale of the resale shares by the selling stockholders. 

We agreed to keep this prospectus effective until the earlier of (i) the date on which the shares may be resold by the selling
stockholders without registration and without the requirement to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144 or (ii) all of the shares have been sold pursuant to this prospectus or
Rule 144 under the Securities Act or any other rule of similar effect. The resale shares will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the
resale shares may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. 

 Under applicable rules and regulations under the Securities Exchange Act of 1934, as amended, any
person engaged in the distribution of the resale shares may not simultaneously engage in market making activities with respect to the Common Stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the
distribution. In addition, the selling stockholders will be subject to applicable provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder, including Regulation M, which may limit the timing of
purchases and sales of shares of the Common Stock by the selling stockholders or any other person. We will make copies of this prospectus available to the selling stockholders and have informed them of the need to deliver a copy of this prospectus
to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act of 1933, as amended). 

 Annex B 

Q THERAPEUTICS, INC. 

Selling Securityholder Notice and questionnaire 

The undersigned beneficial owner of Common Stock (the “Registrable Securities”) of Q Therapeutics, Inc. , a Delaware corporation (the
“Company”), understands that the Company has filed or intends to file with the Securities and Exchange Commission (the “Commission”) a registration statement (the “Registration Statement”) for the
registration and resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), of the Registrable Securities, in accordance with the terms of the Registration Rights Agreement (the “Registration
Rights Agreement”) to which this document is annexed. A copy of the Registration Rights Agreement is available from the Company upon request at the address set forth below. All capitalized terms not otherwise defined herein shall have the
meanings ascribed thereto in the Registration Rights Agreement. 
 Certain legal consequences arise from being named as a selling securityholder in the
Registration Statement and the related prospectus. Accordingly, holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling
securityholder in the Registration Statement and the related prospectus. 
 NOTICE 

The undersigned beneficial owner (the “Selling Securityholder”) of Registrable Securities hereby elects to include the Registrable Securities
owned by it in the Registration Statement. 
 The undersigned hereby provides the following information to the Company and represents and warrants that such
information is accurate: 
 QUESTIONNAIRE 

1. Name. 
 (a) Full Legal Name of Selling Securityholder

  
  

(b) Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held: 

 
  

(c) Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of
the securities covered by this questionnaire): 

 2. Address for Notices to Selling Securityholder: 

 
  
  

 
  

	
	  

Telephone:

	 Fax:

	 Contact Person:

 3. Broker-Dealer Status: 
  

	(a)	Are you a broker-dealer? 

                    Yes     No 

(b) If “yes” to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to the Company? 

                    Yes     No 

Note: If “no” to Section 3(b), the Commission’s staff has indicated that you should be identified as an underwriter in the Registration
Statement. 
 (c) Are you an affiliate of a broker-dealer? 

                    Yes     No 

(d) If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business, and at the
time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities? 

                    Yes     No 

Note: If “no” to Section 3(d), the Commission’s staff has indicated that you should be identified as an underwriter in the Registration
Statement. 
 4. Beneficial Ownership of Securities of the Company Owned by the Selling Securityholder. 

Except as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than the
securities issuable pursuant to the Purchase Agreement. 

 (a) Type and Amount of other securities beneficially owned by the Selling Securityholder: 

 
  
  

 
 5. Relationships with the Company: 

Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the
equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years. 

State any exceptions here: 
  

 
  

 
 The undersigned agrees to promptly notify the Company
of any inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof at any time while the Registration Statement remains effective. 

By signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the inclusion of such
information in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment of
the Registration Statement and the related prospectus. 
 IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and
questionnaire to be executed and delivered either in person or by its duly authorized agent. 
 Date:
                                         
            
  

			
	Beneficial Owner:
		
	By:	 	 
		 	Name:
		 	Title:

 PLEASE FAX A COPY OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE, AND RETURN THE ORIGINAL BY OVERNIGHT MAIL,
TO: 
 Q THERAPEUTICS, INC. 

615 ARAPEEN DRIVE, SUITE 102 

SALT LAKE CITY, UTAH 84108 

Phone: 801-582-5400; Fax: 801-582-5401EX-4.11

 Exhibit 4.11 
  

			
	NO. ____	 	                        Q THERAPEUTICS, INC.

 WARRANT TO PURCHASE COMMON STOCK 

VOID AFTER 5:00 P.M., EASTERN 

TIME, ON THE EXPIRATION DATE 

FOR VALUE RECEIVED, Q THERAPEUTICS, INC., a Delaware corporation (the “Company”), hereby agrees to sell upon the terms
and on the conditions hereinafter set forth, but no later than 5:00 p.m., Mountain Time, on the Expiration Date (as hereinafter defined) to             , or registered assigns (the
“Holder”), under the terms as hereinafter set forth, up to a total of             shares of common stock, $0.0001 par value (the “Common Stock”), of the
Company (all such shares the “Warrant Stock”), at a purchase price of ONE DOLLAR ($1.00) per share (the “Warrant Price”), pursuant to this warrant (this “Warrant”). The number of shares of Warrant
Stock to be so issued and the Warrant Price are subject to adjustment in certain events as hereinafter set forth. 
 1. Exercise of
Warrant. 
 a. The Holder may exercise this Warrant according to its terms by surrendering this Warrant to the Company at the address set
forth in Section 9, the Notice of Exercise attached hereto having then been duly executed by the Holder, accompanied by cash, certified check or bank draft in payment of the purchase price, in lawful money of the United States of America, for
the number of shares of the Warrant Stock specified in the Notice of Exercise, or as otherwise provided in this Warrant, prior to 5:00 p.m., Eastern Time, on             , 2018 (the
“Expiration Date”). 
 b. This Warrant may be exercised in whole or in part so long as any exercise in part hereof would not
involve the issuance of fractional shares of Warrant Stock. If exercised in part, the Company shall deliver to the Holder a new Warrant, identical in form, in the name of the Holder, evidencing the right to purchase the number of shares of Warrant
Stock as to which this Warrant has not been exercised, which new Warrant shall be signed by the Chairman, Chief Executive Officer or President and the Secretary or Assistant Secretary of the Company. The term Warrant as used herein shall include any
subsequent Warrant issued as provided herein. 
 c. No fractional shares or scrip representing fractional shares shall be issued upon the
exercise of this Warrant. If, upon exercise of this Warrant, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exercise, round up or down to the nearest whole number the number of shares of Common Stock
to be issued to the Warrant holder. 

 d. In the event of any exercise of the rights represented by this Warrant, a certificate or
certificates for the Warrant Stock so purchased, registered in the name of the Holder, shall be delivered to the Holder within a reasonable time after such rights shall have been so exercised. The person or entity in whose name any certificate for
the Warrant Stock is issued upon exercise of the rights represented by this Warrant shall for all purposes be deemed to have become the holder of record of such shares immediately prior to the close of business on the date on which the Warrant was
surrendered and payment of the Warrant Price and any applicable taxes was made, irrespective of the date of delivery of such certificate, except that, if the date of such surrender and payment is a date when the stock transfer books of the Company
are closed, such person shall be deemed to have become the holder of such shares at the opening of business on the next succeeding date on which the stock transfer books are open. The Company shall pay any and all documentary stamp or similar issue
or transfer taxes payable in respect of the issue or delivery of shares of Common Stock on exercise of this Warrant. 
 2. Reservation of
Shares. The Company hereby agrees that at all times there shall be reserved for issuance upon the exercise of this Warrant such number of shares of its Common Stock as shall be required for issuance upon exercise of this Warrant. The Company
further agrees that all shares which may be issued upon the exercise of the rights represented by this Warrant will be duly authorized and will, upon issuance and against payment of the exercise price, be validly issued, fully paid and non-assessable, free from all taxes, liens, charges and preemptive rights with respect to the issuance thereof, other than taxes, if any, in respect of any transfer occurring contemporaneously with such issuance and
other than transfer restrictions imposed by federal and state securities laws. 
 3. Warrant Register, Exchange, Transfer or Assignment of
Warrant. 
 The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary. 
 This Warrant is exchangeable, without expense, at the option of the
Holder, upon presentation and surrender hereof to the Company or at the office of its stock transfer agent, if any, for other Warrants of different denominations, entitling the Holder or Holders thereof to purchase in the aggregate the same number
of shares of Common Stock purchasable hereunder. Upon surrender of this Warrant to the Company or at the office of its stock transfer agent, if any, with the Assignment Form annexed hereto duly executed and funds sufficient to pay any transfer tax,
the Company shall, without charge, execute and deliver a new Warrant in the name of the assignee named in such instrument of assignment and this Warrant shall promptly be canceled. This Warrant may be divided or combined with other Warrants that
carry the same rights upon presentation hereof at the office of the Company or at the office of its stock transfer agent, if any, together with a written notice specifying the names and denominations in which new Warrants are to be issued and signed
by the Holder hereof. 

  
 Warrant 2 

 4. Capital Adjustments. This Warrant is subject to the following further provisions: 

a. Adjustment Upon Issuance of Common Stock. If and whenever on or after the date hereof and through the earlier to occur of the
(i) first anniversary of the date hereof and the (ii) date that there is an effective registration statement on file with the Securities and Exchange Commission covering the resale of all of the shares of Warrant Stock the Company issues
or sells any shares of Common Stock or securities convertible into Common Stock, other than an Exempt Issuance (as defined below), for a consideration per share of Common Stock (the “New Issuance Price”) less than a price equal to
$1.00 (subject to appropriate adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction after the date hereof) (a “Dilutive Issuance”), then immediately after such Dilutive Issuance,
the Warrant Price then in effect shall be reduced to an amount equal to the New Issuance Price multiplied by 1.0. For purposes of this Warrant, “Exempt Issuance” shall mean the issuance of (a) shares of Common Stock or options
to employees, officers, directors, or consultants of the Company pursuant to any stock or option plan duly adopted for such purpose by a majority of the non-employee members of the Board of Directors of the Company or a majority of the members of a
committee of non-employee directors, (b) securities upon the exercise or exchange of or conversion of any securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and
outstanding on the date of this Warrant, provided that such securities have not been amended since the date of this Warrant to increase the number of such securities or to decrease the exercise, exchange or conversion price of such securities; and
(c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a person which is either an owner of, or an entity
that is, itself or through its subsidiaries, an operating company in a business synergistic with the business of the Company and in which the Company receives benefits in addition to the investment of funds, but shall not include a transaction in
which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. 

b. Recapitalization, Reclassification and Succession. If any recapitalization of the Company or reclassification of its Common
Stock or any merger or consolidation of the Company into or with a corporation or other business entity, or the sale or transfer of all or substantially all of the Company’s assets or of any successor corporation’s assets to any other
corporation or business entity (any such corporation or other business entity being included within the meaning of the term “successor corporation”) shall be effected, at any time while this Warrant remains outstanding and unexpired, then,
as a condition of such recapitalization, reclassification, merger, consolidation, sale or transfer, lawful and adequate provision shall be made whereby the Holder of this Warrant thereafter shall have the right to receive upon the exercise hereof as
provided in Section 1 and in lieu of the shares of Common Stock immediately theretofore issuable upon the exercise of this Warrant, such shares of capital stock, securities or other property as may be issued or payable with respect to or in
exchange for a number of outstanding shares of Common Stock equal to the number of shares of Common Stock immediately theretofore issuable upon the exercise of this Warrant had such recapitalization, reclassification, merger, consolidation, sale or
transfer not taken place, and in each such case, the terms of this Warrant shall be applicable to the shares of stock or other securities or property receivable upon the exercise of this Warrant after such consummation. 

  
 Warrant 3 

 c. Subdivision or Combination of Shares. If the Company at any time while this Warrant
remains outstanding and unexpired shall subdivide or combine its Common Stock, the number of shares of Warrant Stock purchasable upon exercise of this Warrant and the Warrant Price shall be proportionately adjusted. 

d. Stock Dividends and Distributions. If the Company at any time while this Warrant is outstanding and unexpired shall issue or pay the
holders of its Common Stock, or take a record of the holders of its Common Stock for the purpose of entitling them to receive, a dividend payable in, or other distribution of, Common Stock, then (i) the Warrant Price shall be adjusted in
accordance with Section 4(f) and (ii) the number of shares of Warrant Stock purchasable upon exercise of this Warrant shall be adjusted to the number of shares of Common Stock that the Holder would have owned immediately following such
action had this Warrant been exercised immediately prior thereto. 
 e. Stock and Rights Offering to Shareholders. If the Company
shall at any time after the date of issuance of this Warrant distribute to all holders of its Common Stock any shares of capital stock of the Company (other than Common Stock) or evidences of its indebtedness or assets (excluding cash dividends or
distributions paid from retained earnings or current year’s or prior year’s earnings of the Company) or rights or warrants to subscribe for or purchase any of its securities (excluding those referred to in the immediately preceding
paragraph) (any of the foregoing being hereinafter in this paragraph called the “Securities”), then in each such case, the Company shall reserve shares or other units of such Securities for distribution to the Holder upon exercise of this
Warrant so that, in addition to the shares of the Common Stock to which such Holder is entitled, such Holder will receive upon such exercise the amount and kind of such Securities which such Holder would have received if the Holder had, immediately
prior to the record date for the distribution of the Securities, exercised this Warrant. 
 f. Warrant Price Adjustment. Except as
otherwise provided herein, whenever the number of shares of Warrant Stock purchasable upon exercise of this Warrant is adjusted, as herein provided, the Warrant Price payable upon the exercise of this Warrant shall be adjusted to that price
determined by multiplying the Warrant Price immediately prior to such adjustment by a fraction (i) the numerator of which shall be the number of shares of Warrant Stock purchasable upon exercise of this Warrant immediately prior to such
adjustment, and (ii) the denominator of which shall be the number of shares of Warrant Stock purchasable upon exercise of this Warrant immediately thereafter. 

g. Certain Shares Excluded. The number of shares of Common Stock outstanding at any given time for purposes of the adjustments set forth
in this Section 4 shall exclude any shares then directly or indirectly held in the treasury of the Company. 
 h. Deferral and
Cumulation of De Minimis Adjustments. The Company shall not be required to make any adjustment pursuant to this Section 5 if the amount of such adjustment would be less than one percent (1%) of the Warrant Price in effect immediately
before the event that would otherwise have given rise to such adjustment. In such case, however, any adjustment that would otherwise have been required to be made shall be made at the time of and together with the next subsequent adjustment which,
together with any adjustment or adjustments so carried forward, shall amount to not less than one percent (1%) of the Warrant Price in effect immediately before the event giving rise to such next subsequent adjustment. 

  
 Warrant 4 

 i. Duration of Adjustment. Following each computation or readjustment as provided in this
Section 4, the new adjusted Warrant Price and number of shares of Warrant Stock purchasable upon exercise of this Warrant shall remain in effect until a further computation or readjustment thereof is required. 

5. Call Right. Subject to the provisions of Section 5, this Warrant may be redeemed prior to the Expiration Date, at the option of
the Company, at a price of $0.001 per share of Warrant Stock (“Redemption Price”), upon not less than 10 days prior written notice (“Redemption Period”) to the Holder notifying Holder of the Company’s intent to
exercise such right and setting forth a time and date for such redemption; provided, however, that no redemption under this Section 5 may occur unless (i) the Company’s Common Stock has had a per share closing sales
price of at least equal to or greater than one hundred fifty percent (150%) of the Warrant Price (as proportionately adjusted for any split, combination or the like) for ten (10) consecutive trading days and (ii) at the date of the
redemption notice and during the entire Redemption Period there is an effective registration statement covering the sale of the Warrant Stock. This Warrant may be exercised by the Holder, for cash, at any time after notice of redemption has been
given by the Company and prior to the time and date fixed for redemption, and the other provisions of this Warrant shall remain in full force and effect through and including the redemption date. On and after the redemption date, the Holder shall
have no further rights except to receive, upon surrender of this Warrant, the Redemption Price. 
 6. Notice to Holders. 

a. Notice of Record Date. In case: 

(i) the Company shall take a record of the holders of its Common Stock (or other stock or securities at the time receivable upon the exercise
of this Warrant) for the purpose of entitling them to receive any dividend (other than a cash dividend payable out of earned surplus of the Company) or other distribution, or any right to subscribe for or purchase any shares of stock of any class or
any other securities, or to receive any other right; 
 (ii) of any capital reorganization of the Company, any reclassification of the
capital stock of the Company, any consolidation with or merger of the Company into another corporation, or any conveyance of all or substantially all of the assets of the Company to another corporation; or 

(iii) of any voluntary dissolution, liquidation or winding-up of the Company; 

then, and in each such case, the Company will mail or cause to be mailed to the Holder hereof at the time outstanding a notice specifying, as the case may be,
(i) the date on which a record is to be taken for the purpose of such dividend, distribution or right, and stating the amount and character of such dividend, distribution or right, or (ii) the date on which such reorganization,
reclassification, consolidation, merger, conveyance, dissolution, liquidation or winding-up is to take place, and the time, if any, is to be fixed, as of which the holders of record of Common 

  
 Warrant 5 

 Stock (or such stock or securities at the time receivable upon the exercise of this Warrant) shall be
entitled to exchange their shares of Common Stock (or such other stock or securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, conveyance, dissolution or winding-up. Such notice
shall be mailed at least thirty (30) days prior to the record date therein specified, or if no record date shall have been specified therein, at least thirty (30) days prior to such specified date, provided, however, failure to provide any
such notice shall not affect the validity of such transaction. 
 b. Certificate of Adjustment. Whenever any adjustment shall be made
pursuant to Section 4 hereof, the Company shall promptly make a certificate signed by its Chairman, Chief Executive Officer, President, Vice President, Chief Financial Officer or Treasurer, setting forth in reasonable detail the event requiring
the adjustment, the amount of the adjustment, the method by which such adjustment was calculated and the Warrant Price and number of shares of Warrant Stock purchasable upon exercise of this Warrant after giving effect to such adjustment, and
shall promptly cause copies of such certificates to be mailed (by first class mail, postage prepaid) to the Holder of this Warrant. 
 7.
Loss, Theft, Destruction or Mutilation. Upon receipt by the Company of evidence satisfactory to it, in the exercise of its reasonable discretion, of the ownership and the loss, theft, destruction or mutilation of this Warrant and, in the case
of loss, theft or destruction, of indemnity reasonably satisfactory to the Company and, in the case of mutilation, upon surrender and cancellation thereof, the Company will execute and deliver in lieu thereof, without expense to the Holder, a new
Warrant of like tenor dated the date hereof. 
 8. Warrant Holder Not a Stockholder. The Holder of this Warrant, as such, shall not be
entitled by reason of this Warrant to any rights whatsoever as a stockholder of the Company. 
 9. Notices. Any notice required or
contemplated by this Warrant shall be deemed to have been duly given if transmitted by registered or certified mail, return receipt requested, or nationally recognized overnight delivery service, to the Company at its principal executive
offices located at 615 Arapeen Drive, Suite 102, Salt Lake City, UT 84108. Attention: Steven J. Borst, Chief Financial Officer, or to the Holder at the name and address set forth in the Warrant Register maintained by the Company. 

10. Choice of Law. THIS WARRANT IS ISSUED UNDER AND SHALL FOR ALL PURPOSES BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL
LAWS OF THE STATE OF DELAWARE, WITHOUT GIVING EFFECT TO PRINCIPLES OF CONFLICTS OF LAW. 
 11. Jurisdiction and Venue. The Company and
Holder hereby agree that any dispute which may arise between them arising out of or in connection with this Warrant shall be adjudicated before a court located in Salt Lake City, Utah and they hereby submit to the exclusive jurisdiction of the
federal and state courts of the State of Utah located in Salt Lake City with respect to any action or legal proceeding commenced by any party, and irrevocably waive any objection they now or hereafter may have respecting the venue of any such action
or proceeding brought in such a court or respecting the fact that such court is an inconvenient forum, relating to or arising out of this Warrant or any acts or omissions relating to the sale of the 

  
 Warrant 6 

 
securities hereunder, and consent to the service of process in any such action or legal proceeding by means of registered or certified mail, return receipt requested, in care of the address set
forth herein or such other address as either party shall furnish in writing to the other. 
 [SIGNATURE PAGE FOLLOWS] 

  
 Warrant 7 

 IN WITNESS WHEREOF, the Company has duly caused this Warrant to be signed on its behalf, in its
corporate name and by its duly authorized officers, as of this             day of             , 2014. 

 

			
	Q THERAPEUTICS, INC.
		
	By:	 	 
		 	Name: Deborah A. Eppstein, PhD
		 	Title: President and CEO

  
 Warrant 8 

 NOTICE OF EXERCISE 

 

	TO:	Q THERAPEUTICS, INC. 

 615 ARAPEEN DRIVE 

Suite 102 
 SALT LAKE CITY, UT
84108 
 Attn: Chief Financial Officer 

Tel: (801) 582-5400 
 Fax:
(801) 582-5401 
 (1) The undersigned hereby elects to purchase
            shares of Warrant Stock of the Company pursuant to the terms of the attached Warrant to Purchase Common Stock, and tenders herewith payment of the exercise price or
            Warrants X $1.00 (or adjusted) per share, in the total amount of $            in full, together with all applicable
transfer taxes, if any. 
 (2) Payment shall take the form of lawful money of the United States. 

(3) Please issue a certificate or certificates representing said shares of Warrant Stock in the name and address of the undersigned or in such
other name as is specified below: 
 NAME: 
  

ADDRESS 
  

The shares of Warrant Stock shall be delivered to the following DWAC Account Number, if permitted, or by physical delivery of a certificate
to: 
  
  

 
  
  

 

  
 Warrant 9 

 [SIGNATURE OF HOLDER] 

Name of Investing Entity:                   
                                         
                                         
                                         
                                         
                         

Signature of Authorized Signatory of Investing Entity:            
                                         
                                         
                                         
                   

Name and Title of Authorized Signatory:               
                                         
                                         
                                         
                                         

Date:                         
                                         
                                         
                                         
                                         
                                         
                  
  

  
 Warrant 10 

 ASSIGNMENT FORM 

(To assign the foregoing warrant, execute 

this form and supply required information. 

Do not use this form to exercise the warrant.) 

FOR VALUE RECEIVED, all of or
                    shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to 

 

			
	  
	  	whose address is
	  
	  	
	  
	  	

Dated:                    ,
     

Holder’s Name:                      
                                         
                                         
                                         
                                         
                                         

Holder’s Signature:                     
                                         
                                         
                                         
                                         
                                   

Name and Title of Signatory:                  
                                         
                                         
                                         
                                         
                    

Holder’s Address:                     
                                         
                                         
                                         
                                         
                                      

Signature Guaranteed:                     
                                         
                                         
                                         
                                         
                              

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any
change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant. 

  
 Warrant 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]